© 2018 Miraculo Inc. All Rights Reserved
Inhibition of FAAH and activation of PPAR: New approaches to the treatment of cognitive dysfunction and drug addiction
Cannabinoids are a collection of naturally occurring compounds that are situated in the marijuana plant (cannabis sativa). Cannabidiol (CBD) is the main chemical within the cannabis plant and it is said by the wide scientific community that it has anti inflammatory effects when induced into animal cells. Tetrahydrocannabinol (THC) is another one of these chemicals and it is said to have a psychotropic effect. Cannabinoid receptors (CB1 and CB2) are located in the endocannabinoid system and gives cannabinoids power to bind and thrive in the body. This paper will look at how cannabinoids can be used in the treatment of cognitive dysfunction and drug addiction.
Cannabinoids may have a therapeutic ability
Improving the impacts of endogenously-released cannabinoids in the brain may give off therapeutic effects more safely and efficiently than dosing agents that act directly at the cannabinoid receptor. This paper takes into account recent studies on the effects of cannabinoid receptor activators in animal models of addiction and cognition. These studies illustrate that cannabinoids can give possible therapeutic effects, mostly through cannabinoid receptors. These impacts include increasing certain types of learning, counteracting the rewarding impacts of nicotine and alcohol, alleviating conditions of withdrawal from cannabinoids and different types drugs, and maintaining versus relapse-like reinstatement of drug self dosing Since cannabis induction may hold a collection of therapeutic abilities but may actually share some of the negative side effects of cannabis. Although these regions of study are current, the preliminary results show that they may lead to improved therapeutic involvement and a better knowledge of the brain functions underlying addiction and memory.
Cannabinoids can assist drug addiction treatment
Cannabinoids are coming out as new agents for the treatment of cognitive syndromes and drug addiction. Cannabinoid inhibition may give a means of regulating the endocannabinoid system to gain therapeutic impacts without the unwarranted adverse events related to the dosing of cannabinoid receptor agonists. Some of the impacts of cannabinoids are because of their indirect impacts on cannabinoid receptors, and some are because of its indirect impacts on cannabinoids. Cannabinoid based treatments have not yet been approved for human use, but preclinical research has suggested that they show promise for treating a wide range of cognitive syndromes, including depression, anxiety, memory impairment, post-traumatic stress syndrome, and inflammation-related neurodegeneration.nihms-436392